While missense mutations at G12, G13, and Q61 in KRAS are canonical drivers of lung, pancreas, and colorectal cancers [16], overexpression of wild-type KRAS has been observed in head and neck [17], endometrial [18], ovarian [19], testicular [20], lung [21], gastric [22], colon [23], and bladder cancers [24]. Here, KRAS is linked to urinary bladder cancer.